fda warning letters compounded semaglutide tirzepatide 2024 2025 August 11, 2025: The voices concern about sites that supply compounding ingredients – Partnership for Safe Medicines FDA warns consumers not to

,

New and Improved: This boosted formula, now in stunning new sustainable packaging, delivers next level healthy, beautiful and bright skin

The injection site is located in the middle of the deltoid , which is roughly 2-3 finger widths below the acromion

It increases hepatic glucose output in the short term, which sounds counterintuitive for a metabolic drug, but the body compensates through increased energy expenditure

More recently, a September 4, 2025, inspection found that Strive continued to compound and dispense single-ingredient versions of semaglutide and tirzepatide (the key ingredient in Eli Lillys weight-loss shot) even after the federal shortage exemption period ended earlier that year